World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
108
Citations
73630
World Ranking
5868
National Ranking
331

Overview

Freek W.A. Verheugt is affiliated with the University Medical Centre Mannheim in Germany. Their research primarily spans the field of Medicine, with 108 publications focused within this area.

Their work emphasizes Cardiology and Cardiovascular Medicine, contributing 67 publications in this subfield. Other notable subfields include Internal Medicine, Surgery, Economics and Econometrics, and Psychiatry and Mental Health.

Main research topics explored by Verheugt include:

  • Atrial Fibrillation Management and Outcomes
  • Cardiac Arrhythmias and Treatments
  • Venous Thromboembolism Diagnosis and Management
  • Antiplatelet Therapy and Cardiovascular Diseases
  • Fibromyalgia and Chronic Fatigue Syndrome Research
  • Health Systems, Economic Evaluations, Quality of Life
  • Musculoskeletal Pain and Rehabilitation

Freek W.A. Verheugt has contributed to several frequent publication venues, with a strong presence in the European Heart Journal, where they have published six papers. Other venues include Thrombosis and Haemostasis, Journal of Thrombosis and Haemostasis, Healthcare, and BMJ Open.

Prominent coauthors collaborating with Verheugt include:

  • Karen S. Pieper
  • Sylvia Haas
  • A. John Camm
  • Jean-Pierre Bassand
  • Keith A.A. Fox

Recent papers authored or coauthored by Verheugt cover topics related to atrial fibrillation, antithrombotic regimens, extracorporeal membrane oxygenation, and oral anticoagulants combined with antiplatelets. Notable works include:

  • Optimal Antithrombotic Regimens for Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention, 2020, JAMA Cardiology
  • Veno-arterial extracorporeal membrane oxygenation (ECMO) in patients with cardiogenic shock: rationale and design of the randomised, multicentre, open-label EURO SHOCK trial, 2021, EuroIntervention
  • Bleeding and related mortality with NOACs and VKAs in newly diagnosed atrial fibrillation: results from the GARFIELD-AF registry, 2021, Blood Advances
  • Risks associated with discontinuation of oral anticoagulation in newly diagnosed patients with atrial fibrillation: Results from the GARFIELD-AF Registry, 2021, Journal of Thrombosis and Haemostasis
  • Outcomes Associated With Oral Anticoagulants Plus Antiplatelets in Patients With Newly Diagnosed Atrial Fibrillation, 2020, JAMA Network Open

Best Publications

  • ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM).

    Kenneth Dickstein;Alain Cohen-Solal;Gerasimos Filippatos;John J V McMurray

  • 2012 focused update of the ESC Guidelines for the management of atrial fibrillation

    A. John Camm;Gregory Y.H. Lip

  • ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008

    John Camm;Veronica Dean;Jose Luis Zamorano;Perry M. Elliott

  • Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology.

    Frans Van de Werf;Jeroen Bax;Amadeo Betriu;Carina Blomstrom-Lundqvist

  • 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS).

    Marco Valgimigli;Héctor Bueno;Robert A Byrne;Jean-Philippe Collet

  • Rivaroxaban in Patients with a Recent Acute Coronary Syndrome

    Jessica L. Mega;Eugene Braunwald;Stephen D. Wiviott;Jean-Pierre Bassand

  • 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS

    Marco Valgimigli;Héctor Bueno;Robert A. Byrne;Jean-Philippe Collet

  • Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial

    Willem J. M. Dewilde;Tom Oirbans;Freek W. A. Verheugt;Johannes C. Kelder

  • Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology.

    Frans Van de Werf;Diego Ardissino;Amadeo Betriu;Dennis V. Cokkinos

  • Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome

    John H. Jh Alexander;RD D Renato D. Rd Renato D Lopes;Stefan James;Rakhi Kilaru

  • Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction 38

    Stephen D. Wiviott;Eugene Braunwald;Dominick J. Angiolillo;Simha Meisel

  • Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry.

    Jochem W. van Werkum;Antonius A. Heestermans;A. Carla Zomer;Johannes C. Kelder

  • Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial

    Pascal Vranckx;Marco Valgimigli;Peter Jüni;Christian Hamm

  • Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial

    Frans Van de Werf

  • Early Invasive Versus Selectively Invasive Management for Acute Coronary Syndromes

    Robbert J. de Winter;Fons Windhausen;Jan Hein Cornel;Peter H.J.M. Dunselman

  • Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial.

    Michael E. Farkouh;Howard Kirshner;Robert A. Harrington;Sean Ruland

  • Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial.

    Investigators;John H Alexander;Richard C Becker

  • Gender differences in the management and clinical outcome of stable angina.

    Caroline Daly;Felicity Clemens;Jose L. Lopez Sendon;Luigi Tavazzi

  • Effect of Ranolazine, an Antianginal Agent With Novel Electrophysiological Properties, on the Incidence of Arrhythmias in Patients With Non–ST-Segment–Elevation Acute Coronary Syndrome Results From the Metabolic Efficiency With Ranolazine for Less Ischemia in Non–ST-Elevation Acute Coronary Syndrome–Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) Randomized Controlled Trial

    Benjamin M. Scirica;David A. Morrow;Hanoch Hod;Sabina A. Murphy

  • Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial.

    Robert F. Van Es;Jan J. C. Jonker;Freek W. A. Verheugt;Jaap W. Deckers;Jaap W. Deckers

Frequent Co-Authors

Gregory Y.H. Lip
Gregory Y.H. Lip University of Liverpool
Keith A.A. Fox
Keith A.A. Fox University of Edinburgh
Lars Wallentin
Lars Wallentin Uppsala University
Christopher B. Granger
Christopher B. Granger Duke University
Jurriën M. ten Berg
Jurriën M. ten Berg Erasmus University Rotterdam
Kurt Huber
Kurt Huber Sigmund Freud University Vienna
John H. Alexander
John H. Alexander Duke University
Renato D. Lopes
Renato D. Lopes Duke University
Shinya Goto
Shinya Goto Tokai University
Raffaele De Caterina
Raffaele De Caterina University of Pisa

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Medicine is just one of many ways to build a rewarding career in healthcare. For those looking for flexible learning options, online degrees in related fields offer a convenient path forward. For example, pursuing a health administration degree online can prepare you for leadership roles behind the scenes at clinics, hospitals, or insurance companies.

If your career goals include advanced management roles, consider the growing number of affordable online MHA programs. These graduate degrees focus on the business and policy sides of healthcare, equipping students with the skills to improve patient outcomes on a larger scale.

Some healthcare professionals take the clinical route with advanced nursing, and flexible MSN to DNP programs online can help you reach the highest levels of nursing practice. Pharmacists, on the other hand, can upgrade their qualifications with an online pharmacy degree, opening doors to clinical, research, or policy careers.

These online programs make it possible to transition or advance within the dynamic healthcare industry, often while maintaining professional and personal commitments.

Best Scientists Citing Freek W.A. Verheugt

Trending Scientists

Recently Published Articles